AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18771480 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical levofloxacin 0.5% administered as two preoperative drops and three postoperative drops
Number of subjects: 30
Study 18771480 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical levofloxacin 0.5%
Number of subjects: 30
Study 16478626 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Number of subjects: 231
Study 16478626 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 231
Study 14739817 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal group (12 ml/h basal, 0.05-ml patient-controlled bolus dose)
Number of subjects: 30
Study 14739817 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal-bolus group (8 ml/h basal, 4 ml bolus)
Number of subjects: 30
Study 14739817 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus group (0.3 ml/h basal, 9.9 ml bolus)
Number of subjects: 30
Study 12575604 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuoli Xiaodu Powder (TLXDP) given to Group I before and 7 days after surgical operation
Number of subjects: 38
Study 12575604 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group II) did not receive TLXDP
Number of subjects: 38
Study 9336816 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis of lidocaine 5% with epinephrine 1:50,000
Number of subjects: 36
Study 9336816 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis of mepivacaine 2% with epinephrine 1:50,000
Number of subjects: 36
Study 9336816 — intervention group
Group type: COMPARATOR
Intervention: Preservative-free 0.9% NaCl (control)
Number of subjects: 36
Study 7896428 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat sheet silicone membrane oxygenator (Avecor Kolobow 800‐2A)
Number of subjects: 20
Study 7896428 — intervention group
Group type: COMPARATOR
Intervention: Hollow fibre membrane oxygenator (Dideco Masterflo D‐701)
Number of subjects: 20
Study 3684126 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocolytic (ritodrine hydrochloride 200 micrograms/minute for 20 minutes via continuous intravenous infusion)
Number of subjects: 58
Study 3684126 — intervention group
Group type: COMPARATOR
Intervention: No tocolytic
Number of subjects: 58
Study 3684126 — intervention group
Group type: COMPARATOR
Intervention: No tocolytic (after unsuccessful attempt)
Number of subjects: 58
Study 28826229 — intervention group
Group type: COMPARATOR
Intervention: Provider-administered rapid blood (finger-prick) HIV test (standard of care)
Number of subjects: 305
Study 28826229 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice between SOC or a self-administered oral rapid HIV test with provider supervision
Number of subjects: 305
Study 28826229 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice with option to take an HIV test kit for home use
Number of subjects: 305
Study 28826229 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice arm participants who tested
Number of subjects: 305
Study 28826229 — intervention group
Group type: EXPERIMENTAL
Intervention: Offering a test kit for home use to those who refused testing in the clinic
Number of subjects: 305
Study 27618967 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral pudendal nerve block with 0.33% ropivacaine
Number of subjects: 94
Study 27618967 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tramadol 1.5 mg/kg
Number of subjects: 94
Study 23888359 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 or 12 international units depending on weight)
Number of subjects: 38
Study 23888359 — intervention group
Group type: COMPARATOR
Intervention: Intranasal placebo
Number of subjects: 38
Study 23800312 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg po daily for 3 months
Number of subjects: 154
Study 23800312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 20885202 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) treatment at frequencies of 30, 35, 40, or 50 Hz and amplitudes of 2-4 or 4-6 mm for 1 minute.
Number of subjects: 90
Study 20885202 — intervention group
Group type: COMPARATOR
Intervention: Nonvibration control group
Number of subjects: 90
Study 17900393 — intervention group
Group type: EXPERIMENTAL
Intervention: Group CBT (Cognitive Behavioral Therapy) targeting reduction of distress associated with hallucinations
Number of subjects: 63
Study 17900393 — intervention group
Group type: COMPARATOR
Intervention: Group ST (Supportive Therapy) focusing on improving social integration
Number of subjects: 63
Study 16897271 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant intraportal infusion chemotherapy (IPIC) with 5-fluorouracil (650 mg/m²), leucovorin (45 mg/m²), doxorubicin (10 mg/m²), and cisplatin (20 mg/m²) for 6 cycles, starting 5 to 24 days after surgery.
Number of subjects: 28
Study 16897271 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant intraportal infusion chemotherapy (IPIC) for patients with stage I and II disease.
Number of subjects: 28
Study 16897271 — intervention group
Group type: COMPARATOR
Intervention: Control group (hepatectomy without adjuvant therapy).
Number of subjects: 28
Study 16897271 — intervention group
Group type: COMPARATOR
Intervention: Control group (hepatectomy without adjuvant therapy) for patients with stage I and II disease.
Number of subjects: 28
Study 14498765 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribosomal immunostimulant (Ribomunyl®)
Number of subjects: 2117
Study 14498765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2117
Study 10757152 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (1 g magnesium sulfate in pump prime plus 5 mmol/L in cardioplegic solution)
Number of subjects: 97
Study 10757152 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (5 mmol/L in cardioplegic solution)
Number of subjects: 97
Study 10757152 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (1 g magnesium sulfate added to pump prime)
Number of subjects: 97
Study 10757152 — intervention group
Group type: COMPARATOR
Intervention: Group D (placebo control)
Number of subjects: 97
Study 8640047 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg b.i.d. nebulized budesonide
Number of subjects: 102
Study 8640047 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg b.i.d. nebulized budesonide
Number of subjects: 102
Study 8640047 — intervention group
Group type: COMPARATOR
Intervention: Placebo stage (control group)
Number of subjects: 102
Study 1505648 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (G)
Number of subjects: 0
Study 1505648 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 0
Study 6219089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 113
Study 6219089 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole
Number of subjects: 113
Study 29672817 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural instillation of 50 mL autologous blood 3 days after insertion of chest drain (Group A)
Number of subjects: 47
Study 29672817 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (Group B)
Number of subjects: 47
Study 30419875 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive psychotherapy
Number of subjects: 100
Study 30419875 — intervention group
Group type: COMPARATOR
Intervention: Supportive psychotherapy
Number of subjects: 100
Study 27103127 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 62
Study 27103127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 25483677 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecemotide (L-BLP25)
Number of subjects: 34
Study 25483677 — intervention group
Group type: COMPARATOR
Intervention: Single or multiple low doses of cyclophosphamide
Number of subjects: 34
Study 22743596 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (400 mg bid)
Number of subjects: 160
Study 22743596 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 160
Study 19667251 — intervention group
Group type: EXPERIMENTAL
Intervention: olmesartan/azelnidipine (20.0 mg and 16.0 mg)
Number of subjects: 207
Study 19667251 — intervention group
Group type: COMPARATOR
Intervention: olmesartan/hydrochlorothiazide (20.0 mg and 12.5 mg)
Number of subjects: 207
Study 17475737 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT
Number of subjects: 24
Study 17475737 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine
Number of subjects: 24
Study 15851259 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate control (n = 160)
Number of subjects: 335
Study 15851259 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control (n = 175)
Number of subjects: 335
Study 15851259 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control (sinus rhythm at study end)
Number of subjects: 335
Study 15851259 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation at study end
Number of subjects: 335
Study 15851259 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension and no use of angiotensin-converting enzyme inhibitors
Number of subjects: 335
Study 12386569 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) levels
Number of subjects: 15
Study 12386569 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin T (TnT) levels
Number of subjects: 15
Study 12386569 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial diameter
Number of subjects: 15
Study 12386569 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular end-diastolic diameter (LVEDD) and ejection fraction (EF)
Number of subjects: 15
Study 9537210 — intervention group
Group type: EXPERIMENTAL
Intervention: SK&F107647 at 0.01 ng/kg
Number of subjects: 16
Study 9537210 — intervention group
Group type: EXPERIMENTAL
Intervention: SK&F107647 at 0.1 ng/kg
Number of subjects: 16
Study 9537210 — intervention group
Group type: EXPERIMENTAL
Intervention: SK&F107647 at 1.0 ng/kg
Number of subjects: 16
Study 9537210 — intervention group
Group type: EXPERIMENTAL
Intervention: SK&F107647 (dose range 0.01 to 100 ng/kg)
Number of subjects: 16
Study 9537210 — intervention group
Group type: EXPERIMENTAL
Intervention: SK&F107647
Number of subjects: 16
Study 7699836 — intervention group
Group type: EXPERIMENTAL
Intervention: SY5555 5 mg/kg
Number of subjects: 22
Study 7699836 — intervention group
Group type: EXPERIMENTAL
Intervention: SY5555 10 mg/kg
Number of subjects: 22
Study 2679037 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g carbohydrate as potato
Number of subjects: 6
Study 2679037 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g carbohydrate as spaghetti
Number of subjects: 6
Study 2679037 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g protein added to both meals
Number of subjects: 6
Study 2679037 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g protein and 25 g fat added to mashed potato
Number of subjects: 6
Study 334216 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine 75 mg alone
Number of subjects: 10
Study 334216 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam 15 mg
Number of subjects: 10
Study 334216 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam 30 mg
Number of subjects: 10
Study 334216 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine 75 mg with Clobazam 15 mg
Number of subjects: 10
Study 334216 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine 75 mg with Clobazam 30 mg
Number of subjects: 10
Study 31481069 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 14671
Study 31481069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14671
Study 28063876 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast (at least 15% of daily energy requirement before 8:30 a.m.)
Number of subjects: 49
Study 28063876 — intervention group
Group type: COMPARATOR
Intervention: No breakfast (no energy until after 11:30 a.m.)
Number of subjects: 49
Study 25997686 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS)
Number of subjects: 86
Study 25997686 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 86
Study 23870702 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model for relaparotomy decision-making
Number of subjects: 182
Study 22127708 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg belimumab plus standard therapy
Number of subjects: 819
Study 22127708 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg belimumab plus standard therapy
Number of subjects: 819
Study 22127708 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard therapy
Number of subjects: 819
Study 22127708 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg belimumab
Number of subjects: 819
Study 22127708 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg belimumab
Number of subjects: 819
Study 22127708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 819
Study 19567505 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen test
Number of subjects: 39389
Study 17908055 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant vaccination with ZOSTAVAX and inactivated influenza vaccine
Number of subjects: 762
Study 17908055 — intervention group
Group type: COMPARATOR
Intervention: Sequential vaccination with ZOSTAVAX and inactivated influenza vaccine
Number of subjects: 762
Study 17908055 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant vaccination
Number of subjects: 762
Study 17908055 — intervention group
Group type: COMPARATOR
Intervention: Sequential vaccination
Number of subjects: 762
Study 15516645 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine and albendazole therapy (DEC/ALB)
Number of subjects: 58
Study 11600924 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (exercise program with ergonomic education, administered twice a week for four months)
Number of subjects: 0
Study 11600924 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9783495 — intervention group
Group type: EXPERIMENTAL
Intervention: Older hypertensive patients (OHT)
Number of subjects: 46
Study 9783495 — intervention group
Group type: COMPARATOR
Intervention: Older normotensive patients (OHS)
Number of subjects: 46
Study 7824594 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0
Study 7824594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3135204 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of slow-release terbutaline
Number of subjects: 14
Study 3135204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31219027 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing (revealed arm)
Number of subjects: 24496
Study 31219027 — intervention group
Group type: COMPARATOR
Intervention: Cytology (concealed arm)
Number of subjects: 24496
Study 31219027 — intervention group
Group type: EXPERIMENTAL
Intervention: New HPV infection at round 2
Number of subjects: 24496
Study 31219027 — intervention group
Group type: EXPERIMENTAL
Intervention: Type-specific persistent infections
Number of subjects: 24496
Study 31219027 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV infection with normal cytology
Number of subjects: 24496
Study 31219027 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent HPV infections
Number of subjects: 24496
Study 28699417 — intervention group
Group type: EXPERIMENTAL
Intervention: MoM (Metasul)
Number of subjects: 30
Study 28699417 — intervention group
Group type: COMPARATOR
Intervention: MoP (Protasul)
Number of subjects: 30
Study 25046578 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative writing intervention
Number of subjects: 70
Study 25046578 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study 25046578 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between groups
Number of subjects: 70
Study 23639625 — intervention group
Group type: EXPERIMENTAL
Intervention: $30 Australian Dollars cash following receipt of vaccine doses two and three
Number of subjects: 139
Study 23639625 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 139
Study 21518554 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (15 mg) as a single dose before reperfusion and another 15 mg at 24 hours post-operation
Number of subjects: 23
Study 21518554 — intervention group
Group type: COMPARATOR
Intervention: Anti-thymocyte globulin (ATG) (9 mg/kg) given 2 hours before kidney transplantation
Number of subjects: 23
Study 21518554 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 23
Study 21518554 — intervention group
Group type: COMPARATOR
Intervention: Anti-thymocyte globulin (ATG)
Number of subjects: 23
Study 21518554 — intervention group
Group type: COMPARATOR
Intervention: ATG
Number of subjects: 23
Study 21518554 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 23
Study 18676038 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month exercise-based Cardiac Rehabilitation (CR) program
Number of subjects: 60
Study 18676038 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 16740113 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychopathic violent offenders (P-VO)
Number of subjects: 0
Study 16740113 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpsychopathic violent offenders (NP-VO)
Number of subjects: 0
Study 16740113 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent offenders (VO)
Number of subjects: 0
Study 16740113 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychopathy
Number of subjects: 0
Study 14594020 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous enfuvirtide added to an optimized oral background antiretroviral regimen
Number of subjects: 0
Study 14594020 — intervention group
Group type: COMPARATOR
Intervention: Optimized oral background antiretroviral regimen
Number of subjects: 0
Study 10880321 — intervention group
Group type: EXPERIMENTAL
Intervention: Various therapies administered to patients
Number of subjects: 124
Study 8883925 — intervention group
Group type: EXPERIMENTAL
Intervention: Language stimuli (bisyllablic content words)
Number of subjects: 12
Study 8883925 — intervention group
Group type: COMPARATOR
Intervention: Non-language stimuli (physically similar non-language stimuli)
Number of subjects: 12
Study 8883925 — intervention group
Group type: EXPERIMENTAL
Intervention: Language stimuli (auditory condition)
Number of subjects: 12
Study 8883925 — intervention group
Group type: COMPARATOR
Intervention: Non-language stimuli (visual condition)
Number of subjects: 12
Study 8883925 — intervention group
Group type: EXPERIMENTAL
Intervention: Language and non-language stimuli
Number of subjects: 12
Study 8883925 — intervention group
Group type: EXPERIMENTAL
Intervention: Language stimuli
Number of subjects: 12
Study 1548251 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 83
Study 1548251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 1548251 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine and Placebo
Number of subjects: 83
Study 3856578 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group (T) received prophylaxes according to a previously described schedule and based on DDFM test outcome. Recall intervals ranged from 1 to 24 months (mean: 15.7 months).
Number of subjects: 69
Study 3856578 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) received regular prophylaxes every 6 months.
Number of subjects: 69
Study 3856578 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group (T) and Control group (C)
Number of subjects: 69
Study 3856578 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 69
Study 3856578 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group (T)
Number of subjects: 69
Study 3856578 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (C and T)
Number of subjects: 69
Study 29486796 — intervention group
Group type: EXPERIMENTAL
Intervention: Deworming treatment
Number of subjects: 0
Study 27650605 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality protein supplementation
Number of subjects: 12
Study 27650605 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-quality protein supplementation
Number of subjects: 12
Study 24858376 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g TRP-rich protein hydrolysate
Number of subjects: 60
Study 24858376 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g TRP-rich protein hydrolysate
Number of subjects: 60
Study 24858376 — intervention group
Group type: COMPARATOR
Intervention: 3.11 g casein hydrolysate
Number of subjects: 60
Study 22391955 — intervention group
Group type: EXPERIMENTAL
Intervention: High-voltage electrical stimulation (HVES) at 100 V, 100 μs, 100 Hz for 50 minutes once daily, five times per week
Number of subjects: 50
Study 22391955 — intervention group
Group type: COMPARATOR
Intervention: Standard supportive care and topical treatments with wet-to-moist dressings
Number of subjects: 50
Study 20718163 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid simethicone (2 ml in 60 ml of water)
Number of subjects: 121
Study 20718163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 17914010 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of planned behavior guided class
Number of subjects: 94
Study 17914010 — intervention group
Group type: COMPARATOR
Intervention: Standard continuing education class
Number of subjects: 94
Study 15948782 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.2‐mm arched blade
Number of subjects: 74
Study 15948782 — intervention group
Group type: COMPARATOR
Intervention: 3.2‐mm flat blade
Number of subjects: 74
Study 12351481 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion (10 IU of regular insulin)
Number of subjects: 19
Study 12351481 — intervention group
Group type: COMPARATOR
Intervention: Saline alone (50 ml saline)
Number of subjects: 19
Study 10493689 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic JRA
Number of subjects: 33
Study 10493689 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligo and polyarticular JRA
Number of subjects: 33
Study 10493689 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 33